BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC
( February 12, 2026, 17:17 GMT | Official Statement) -- MLex Summary: BioMarin Pharmaceutical Inc.'s $4.8 billion acquisition of Amicus Therapeutics received approval in the US through an early termination by the US Federal Trade Commission, the agency announced. The Hart-Scott-Rodino Act waiting period was set to expire on Feb. 20, but the companies received the green light on Feb. 11. The transaction was expected to close in the second quarter of 2026.See excerpt....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.